Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

DarshanTalks Podcast

Science Society & Culture Education

Episodes

Showing 1-100 of 303
Page 1 of 4 Next → »»

What Happens When a Sponsor Walks Away Early?

23 Dec 2025

Contributed by Lukas

 Early termination by a sponsor can leave a clinical research site holding the bill for prep work, fees, and staffing. In this episode, Darshan expla...

Cosmetic Claims the FDA Hates

22 Dec 2025

Contributed by Lukas

Your skincare product may look like a cosmetic, but one wrong claim can legally turn it into an unapproved drug.In this episode of KLF Deep Dive, we b...

Biggest Legal Mistakes in Influencer Marketing

18 Dec 2025

Contributed by Lukas

Influencers can boost visibility fast, but they also create real regulatory exposure if they go off script. The FTC requires influencers to clearly di...

Your Mood, Energy, and Sleep Claims Might Be Regulated

11 Dec 2025

Contributed by Lukas

 A lot of brands start with harmless wellness promises like better mood, more energy, or improved sleep. As the business grows, though, marketing oft...

Device Fail: The Legal Anatomy of a Faulty Implant Scandal

10 Dec 2025

Contributed by Lukas

 A knee implant meant to restore mobility. A surgeon secretly collecting international trips and consulting checks. A device company accused of selli...

5 Documents the FDA Will Demand on Site — Are You Ready?

09 Dec 2025

Contributed by Lukas

In this episode of DarshanTalks, you dive into what U.S. Food and Drug Administration (FDA) inspectors will demand when they show up on-site. You walk...

Cosmetic Marketing Mistakes That Trigger Regulators

04 Dec 2025

Contributed by Lukas

 Beauty brands hit trouble when they forget they’re dealing with two regulators, not one. The FDA controls how cosmetics are labeled and when a cla...

Why Your Clinical Trial Contract Is Leaving Cash on the Table

02 Dec 2025

Contributed by Lukas

Clinical research sites lose money when sponsor contracts skip the real costs of running a study. In this episode, Darshan breaks down how to protect ...

Why Testimonials Can Get Your Brand Sued

29 Nov 2025

Contributed by Lukas

Before-and-after photos and glowing testimonials can sell products fast, but they’re also some of the most heavily scrutinized tools in advertising....

How to Get Sponsors to Pay Faster than Net 90

27 Nov 2025

Contributed by Lukas

 Can I negotiate faster payment terms so I don't run out of cash flow? Many sponsor contracts set 90 to 120 day payment timelines. This, however...

Pharma merger killers

14 Nov 2025

Contributed by Lukas

Darshan Kulkarni explores why compliance isn’t just a side issue—it’s often the ultimate dealbreaker in pharma and biotech transactions.When buy...

Balance FDA Rules with FTC Advertising Requirements

12 Nov 2025

Contributed by Lukas

Brands often struggle to balance FDA cosmetic rules with FTC advertising standards. The FDA oversees labeling and determines whether a product is a co...

Key Clauses in PI Contracts to Review

10 Nov 2025

Contributed by Lukas

Many clinical trial site leaders overlook critical risks hidden in physician employment agreements. These contracts often contain clauses that can exp...

Compliance guru talks practical Insights on Speaker Programs

07 Nov 2025

Contributed by Lukas

In this episode, host Darshan Kulkarni speaks with Joseph Keeney about speaker programs in the life sciences industry, exploring practical differences...

Trends in Small Life Sciences Transactions

05 Nov 2025

Contributed by Lukas

Darshan Kulkarni in conversation with Nella Bloom, for an in-depth discussion on the current state of small business transactions, private equity tren...

Protect Your Site If a Sponsor Terminates Early

03 Nov 2025

Contributed by Lukas

When sponsors terminate a clinical trial early, research sites may face financial losses for preparatory or ongoing work. To mitigate this risk, contr...

Are Pharma Chatbots Putting You at Regulatory Risk?

01 Nov 2025

Contributed by Lukas

Pharmaceutical chatbots are increasingly used to answer patient drug questions, but they carry significant regulatory and compliance risks. While the ...

Are Your Cosmetic Company Records Ready for FDA Audits?

30 Oct 2025

Contributed by Lukas

Companies must maintain thorough records to meet FDA inspection requirements, including safety substantiation files, labeling proofs, ingredient docum...

When Medical Affairs Becomes Commercial in Disguise

24 Oct 2025

Contributed by Lukas

Darshan explores a critical question for life sciences companies: is your medical affairs team truly independent from commercial—or are you just pre...

Serious Adverse Event Reporting Under MoCRA

22 Oct 2025

Contributed by Lukas

Under the Modernization of Cosmetics Regulation Act (MoCRA), reporting serious adverse events to the FDA is now mandatory. Companies must report serio...

Key SOPs for Clinical Trials

20 Oct 2025

Contributed by Lukas

Darshan Kulkarni highlights that to stay compliant with the FDA, companies don’t need an exhaustive set of SOPs—just the essential ones. Inspector...

Payer Presentations Can Trigger Enforcement

18 Oct 2025

Contributed by Lukas

The boundary between scientific exchange and marketing in payer presentations is increasingly blurred, creating significant compliance and enforcement...

Pharmacies v manufacturers

16 Oct 2025

Contributed by Lukas

In this episode, Darshan Kulkarni speaks with Dae Lee about the growing conflict between pharmaceutical manufacturers and pharmacy benefit managers (P...

Is Clinical Research Ready for the new FDA?

13 Oct 2025

Contributed by Lukas

The FDA has criticized the industry for not taking advertising and promotion seriously and is now cracking down, as evidenced by hundreds of non-compl...

Is your cosmetics company FDA-registered?

11 Oct 2025

Contributed by Lukas

Cosmetics companies must now register both their facilities and products with the FDA under the new MoCRArequirements, a shift from the previous volun...

Will AI Replace Doctors in clinical research?

09 Oct 2025

Contributed by Lukas

Darshan discusses the potential role of AI in medicine. He believes fears of AI replacing doctors for diagnosis are currently overblown, as trust in p...

Risks in Direct-to-Patient Engagement

07 Oct 2025

Contributed by Lukas

Direct-to-Patient (DTP) models are transforming how medications reach patients, moving beyond clinical research into commercial distribution. Original...

Inside 340B: Challenges, Controversies, and Opportunities

01 Oct 2025

Contributed by Lukas

Darshan Kulkarni speaks with Thomas Siepka, CEO of HCI Healthcare Consultants, to take a deep dive into the often-misunderstood world of the 340B drug...

IRBs in 2025: What’s Really Changing?

27 Sep 2025

Contributed by Lukas

In this conversation, Edye Edens with Nyssa Towsley from UNLV, examine how today’s shifting funding landscape is reshaping IRB operations. Historica...

3 Red Flags in Telemedicine Partnerships

25 Sep 2025

Contributed by Lukas

In this video, Darshan discusses recent enforcement trends show three weak spots to watch:Encounter Quality – If prescribers are just checking boxes...

What do PBMs do?

21 Sep 2025

Contributed by Lukas

In this episode, Darshan Kulkarni talks with Thomas Siepka about the 340B program, rebates, and the crucial role of pharmacy benefit managers (PBMs) i...

How AMCs Build Stronger Compliance Cultures Together

19 Sep 2025

Contributed by Lukas

 In the episode of a new series on academic medical centers, Edye Edens of Kulkarni Law Firm sits down with Cortni Romaine of Florida Atlantic Univer...

How One DME Scheme Cost Medicare $61 Million

15 Sep 2025

Contributed by Lukas

In one of the largest recent Medicare fraud cases, Peter Roussonicolos, a Florida durable medical equipment (DME) company owner, was sentenced to 12 y...

FDA to Step Up Enforcement on Pharma Advertising

12 Sep 2025

Contributed by Lukas

The FDA has recently stepped up its enforcement of pharmaceutical advertising rules, issuing 100 cease-and-desist notices and thousands of letters. Th...

Top 5 Factors Determining AMC Funding

09 Sep 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens launch an exciting new episode, focusing on the unique challenges academic medical centers (AMCs) face in securing fun...

New Series Drop: Exploring AMCs in Clinical Research

06 Sep 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens are kicking off a brand-new video series diving into the unique world of academic medical centers (AMCs) in clinical r...

Why Choose a Licensed Attorney Over a Consultant?

04 Sep 2025

Contributed by Lukas

Edye Edens and Darshan Kulkarni share the origin story of KLF and explain what makes working with licensed attorneys different from hiring non-legal c...

Marketing Problems by Hims & Hers and Lilly

02 Sep 2025

Contributed by Lukas

Telehealth and pharma are facing some of their biggest compliance challenges yet—and the latest enforcement actions prove regulators aren’t slowin...

Should Sponsors Share Site Feedback?

29 Aug 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens examine whether sponsors should provide feedback to clinical trial sites on why they were selected—or not—for a st...

AI Marketing Playbook for Drug Companies

26 Aug 2025

Contributed by Lukas

AI is no longer a distant concept in pharma marketing—it’s here, transforming campaign design, review, and distribution. CEOs and CMOs face a crit...

Should Sites Be Ready on Standby?

23 Aug 2025

Contributed by Lukas

Edye Edens and Darshan Kulkarni from KLF discuss the pros and cons for clinical trial sites considering becoming backup sites. Key points include:Spon...

Eastern District of PA Targets Pharmacies

21 Aug 2025

Contributed by Lukas

The Eastern District of Pennsylvania has ramped up False Claims Act enforcement against pharmacies, with cases ranging from multi-million dollar settl...

Telehealth Done Right

18 Aug 2025

Contributed by Lukas

The Office of Inspector General (OIG) recently issued an advisory opinion approving a telehealth business model where a management company leases clin...

DOJ and HHS Launch FCA Fraud Task Force

15 Aug 2025

Contributed by Lukas

In Fiscal Year 2024, whistleblower cases reached an all-time high of 979, signaling increased scrutiny of healthcare fraud. Just days after announcing...

Should Sponsors Cover Malpractice Insurance?

13 Aug 2025

Contributed by Lukas

Darshan and Edye tackle a hot topic in clinical research budgeting: Should malpractice insurance be considered an overhead cost that sponsors cover?E...

Instagram Post that Sparked FDA Warning Letter

11 Aug 2025

Contributed by Lukas

In this episode, Darshan Kulkarni unpacks the May 29, 2025 FDA Warning Letter issued to Sprout Pharmaceuticals. The trigger? A promotional Instagram p...

Why Are So Many Doctors Getting Arrested?

09 Aug 2025

Contributed by Lukas

Why are headlines suddenly filled with stories of doctors, nurses, healthcare executives—and even accountants—being arrested for fraud? In this ex...

How to Run Compliant Pharma Speaker Programs

06 Aug 2025

Contributed by Lukas

What really happens behind the scenes of pharmaceutical speaker programs—and why should smaller pharma companies care? In this episode of DarshanTal...

​​Are You Picking the Wrong KOLs?

04 Aug 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens tackle the complexities of identifying and working with Key Opinion Leaders (KOLs) in clinical research. While KOLs ca...

How KLF’s Client Base Evolved Over 20 Years

02 Aug 2025

Contributed by Lukas

Edye Edens interviews Darshan Kulkarni about the evolution of the Kulkarni Law Firm (KLF). Darshan reflects on how he originally envisioned working wi...

FDA Pushback on Accelerated Gene Therapy Approvals

31 Jul 2025

Contributed by Lukas

In this episode, Edye Edens dives into the FDA’s evolving scrutiny of accelerated approvals in gene therapy and rare diseases. Using the example of ...

Your DEI Program Could Trigger an FCA Case

30 Jul 2025

Contributed by Lukas

Darshan Kulkarni breaks down the Department of Justice’s new Civil Rights Fraud Initiative, launched on May 19, 2025, and why it should be on the ra...

Teva’s Charity Partnership Scrutinized

28 Jul 2025

Contributed by Lukas

A recent $425 million settlement involving Teva Pharmaceuticals highlights the legal and ethical risks charities face when partnering with pharmaceuti...

Is There a “Right” Way to Calculate FMV?

25 Jul 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens take a deep dive into one of clinical research’s most persistent questions: how is fair market value (FMV) actually ...

Can Non-Physicians Own Clinical Trial Sites?

23 Jul 2025

Contributed by Lukas

Can non-physicians own independent clinical trial sites? The answer isn’t as simple as it seems. In most states, including Texas, engaging in clinic...

The KLF Story You Haven’t Heard

20 Jul 2025

Contributed by Lukas

In this special episode, Senior Attorney Edye Edens sits down with Darshan Kulkarni, founder and principal of the Kulkarni Law Firm, for a personal an...

Why Telehealth Platforms Are Getting Sued

17 Jul 2025

Contributed by Lukas

We explore the growing wave of class action lawsuits hitting the telehealth industry—and why legal counsel, especially those advising telemedicine p...

Should Clinical Trial Sites Be Paid Differently?

15 Jul 2025

Contributed by Lukas

In this episode of the KLF Deep Dive, Darshan Kulkarni and Edye Edens engage in a practical discussion around one of the most debated issues in clinic...

How to Build an AI Compliance Program

14 Jul 2025

Contributed by Lukas

In this episode of KLF Deep Dive, Darshan Kulkarni explores the growing urgency for in-house counsel to develop AI compliance programs as artificial i...

What the Big Beautiful Bill Means for Trial Sites

11 Jul 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens examine the far-reaching implications of the newly passed “Big Beautiful Bill”—a sweeping piece of legislation t...

Co-Pay Mistakes Can Trigger DOJ Action

09 Jul 2025

Contributed by Lukas

In Alvarez v. Lincare, the Eleventh Circuit highlighted a growing risk for pharma marketers and legal teams running Direct-to-Patient (DTP) campaigns....

NIH Grant Denials Ruled Discriminatory?

08 Jul 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens break down a recent federal court ruling that challenges the NIH’s decision to halt grant funding for projects focus...

Are Speaker programs supposed to be salesy?

04 Jul 2025

Contributed by Lukas

Pharmaceutical speaker programs come in two forms: one aimed at promoting a product, and another focused purely on education. Both must be compliant, ...

DTP Compliance Just Got Tricky

28 Jun 2025

Contributed by Lukas

The Seventh Circuit just issued a pivotal decision in U.S. v. Sorenson, reshaping how pharmaceutical and medical device companies should think about d...

Should You Use AI to Draft Informed Consent?

26 Jun 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens discuss the potential and pitfalls of using AI—like ChatGPT—to draft informed consent documents in clinical resear...

Could You Survive a Surprise Pharmacy Audit?

23 Jun 2025

Contributed by Lukas

Imagine you're filling a script when a State Board of Pharmacy inspector walks in—no warning, just a clipboard and serious consequences. Most c...

Self-Reporting in Clinical Trials

20 Jun 2025

Contributed by Lukas

In this video, Edye Edens and Darshan Kulkarni discuss whether sponsors, sites, CROs, or IRBs should self-report compliance issues. Edye, who focuses ...

$14M Fine Says This “Free” Offer Wasn’t Legal

18 Jun 2025

Contributed by Lukas

In this must-listen episode for pharma marketers and corporate counsel, we break down the recent $14.25M False Claims Act settlement involving Diopsys...

Nonprofit Pharma Exists. Here is how it works

16 Jun 2025

Contributed by Lukas

In this episode, we talk to Martin Van Trieste about Civica Rx, nonprofit pharmaceutical company designed to address drug shortages in the U.S. The co...

FTC Rules for Pharma Companies

14 Jun 2025

Contributed by Lukas

In this discussion, Joseph Wolfson, an attorney at Stevens and Lee, and Darshan explore the intersection of law, marketing, and compliance in the phar...

Whistleblowing in Clinical Trials: Is It Worth the Risk?

12 Jun 2025

Contributed by Lukas

In this episode, Darshan Kulkarni and Edye Edens explore whether sites should consider whistleblowing on non-compliant sponsors. They acknowledge that...

The Right Way to Do Medical Affairs on LinkedIn

09 Jun 2025

Contributed by Lukas

In this episode, Darshan Kulkarni sits down with Marie Ange Noue, Senior Director and Head of Scientific Communications at EMD Serono, to dive deep in...

Are We Paying Clinical Trial Patients Enough?

07 Jun 2025

Contributed by Lukas

In this episode, Edye and Darshan dive into the controversial but critical question: Are we paying patients enough to participate in clinical trials? ...

Pharma Ads Are Getting Canceled

04 Jun 2025

Contributed by Lukas

Google’s 2024 ad safety report just sent shockwaves through the pharma and device industries. With AI now faster, smarter, and more ruthless, Google...

Unpacking Screen Fail Payments in Research

31 May 2025

Contributed by Lukas

In this episode Edye Edens and Darshan Kulkarni tackle a hot-button issue in clinical trials: Should all screen fails be paid for? The discussion was ...

Post-Trump Antitrust Rules Are Crushing Pharma Deals

28 May 2025

Contributed by Lukas

In this episode, we explore a crucial and timely issue: how the Trump administration’s approach to antitrust enforcement—combined with new state-l...

7 Must-Know Steps to transfer medical device ownership

24 May 2025

Contributed by Lukas

Transferring medical device ownership during a company sale requires careful planning to ensure compliance and operational continuity. The process beg...

Responding to Site Findings

22 May 2025

Contributed by Lukas

At first glance, responding to site-level findings seems simple—but when Edye and Darshan dug into the details, it became clear that the lines of re...

Is Your Medical Website Illegal?

20 May 2025

Contributed by Lukas

Medical communications teams must exercise caution when using websites dedicated to medical affairs, as legal risks go beyond overt sales promotion. D...

Price Fixing in Clinical Research

17 May 2025

Contributed by Lukas

At the Save Our Sites (SOS) conference, many site owners expressed excitement over finally having a space to openly discuss real challenges—budgets,...

DOJ Cracks Down on Pharmacy Fraud

15 May 2025

Contributed by Lukas

The recent conviction of a Michigan pharmacist and his brother in a $15 million healthcare fraud scheme highlights the growing crackdown on pharmacy-r...

Protect Your DTP Strategy

13 May 2025

Contributed by Lukas

Pharma is finally catching up to the on-demand world—offering direct-to-patient (DTP) services that promise convenience, faster delivery, and a more...

AI Clinical Trial Negotiators

10 May 2025

Contributed by Lukas

Today, we're diving into a hot topic in clinical trials: should you use AI to negotiate your next clinical trial agreement? Darshan is joined by ...

SOPs: How Many is Too Many?

09 May 2025

Contributed by Lukas

In this discussion, Edye Edens and Darshan Kulkarni tackle one of the most common questions in clinical research: How many SOPs should a site have? Wh...

Is DTP Pharma’s Next Big Move?

07 May 2025

Contributed by Lukas

In a recent interview between Nirpal Virdee and Darshan Kulkarni, they discussed the ongoing shifts in the pharmaceutical industry, particularly the r...

Hackers Are Stealing Your Personal Health Data

05 May 2025

Contributed by Lukas

Health records are one of the top targets for hackers. These records contain a wealth of personal information like Social Security numbers, insurance ...

How a “Medical Education” Program Became a $202M Fraud

03 May 2025

Contributed by Lukas

We unpack the $202 million storm surrounding Gilead’s so-called “educational” speaker programs — and why it should make every medical affairs,...

Webinar Recap: What Sponsors Must Know About Fraud

01 May 2025

Contributed by Lukas

After our first-ever deep dive webinar on ‘Protecting Sponsors, Fraud & Compliance in Research,’ Darshan Kulkarni, Edye Edens, and Nirpal Vird...

AI-Powered Engagement is a Minefield

29 Apr 2025

Contributed by Lukas

AI voice tech might be the next big privacy risk for pharma marketers, and lawsuits are already in motion. In this episode of Darshan Talks, we dive i...

Webinar Update: Fraud Prevention Strategies Every Sponsor Needs

24 Apr 2025

Contributed by Lukas

Event details- https://www.linkedin.com/events/protectingsponsors-fraudandcomp7318667647213002752/comments/Registration Link- https://us02web.zoom.us/...

Are Your Promotional Claims Putting Your Company at Risk?

23 Apr 2025

Contributed by Lukas

Guardant Health’s recent $292 million victory against Natera in a false advertising lawsuit sets a critical precedent for the biotech industry, high...

Privacy Dangers Lurking in Clinical Trial Mergers

21 Apr 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens discuss the critical role of data privacy in clinical trial site acquisitions. While privacy concerns can seem dauntin...

The FDA's Crisis Is Now Your Problem

18 Apr 2025

Contributed by Lukas

The FDA you designed your protocol around may no longer exist. In this episode, Darshan Kulkarni breaks down why clinical researchers, regulatory atto...

Broken FDA, Big Consequences

16 Apr 2025

Contributed by Lukas

The FDA is facing unprecedented turmoil—staff cuts, a sweeping reorganization, and political interference are undermining its ability to safeguard p...

You are now the Healthcare Provider - The Future of Health Insurance: Trends, Challenges, and Innovations

14 Apr 2025

Contributed by Lukas

In this episode, Kate Woods and Darshan Kulkarni discussed the shift from employer-sponsored health insurance to individual responsibility, a transiti...

Essential Due Diligence Steps for Clinical Research M&A

12 Apr 2025

Contributed by Lukas

When mergers and acquisitions intersect with clinical trials, due diligence becomes a crucial step in ensuring a successful transition. In this insigh...

Is AI Telemarketing Strategy Illegal?

10 Apr 2025

Contributed by Lukas

Today’s episode is a wake-up call for pharma marketers launching telehealth campaigns. If you're using AI voice assistants or call automation t...

No Clinical Trial Waste

08 Apr 2025

Contributed by Lukas

In this episode, Darshan Kulkarni explores an important yet often overlooked question—what happens after a clinical trial ends? While much focus is ...

The Real Meaning of Audit-Readiness in Clinical Research

06 Apr 2025

Contributed by Lukas

Edye Edens discusses what it truly means to be site audit ready and dispels the misconception that it requires 100% compliance. No auditor expects per...

Ordinary People Are Changing Medicine

04 Apr 2025

Contributed by Lukas

Citizen biohacking is an empowering movement where individuals take medical innovation into their own hands, often stepping in when traditional medici...

Page 1 of 4 Next → »»